Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMV pp65 Specific T Cells
- Development stage
- Unknown
- Lead developer
- Duke University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CMV pp65 Specific T Cells is an investigational adoptive cell therapy developed by H. Kim Lyerly and colleagues at Duke University for the treatment and prevention of cytomegalovirus (CMV) infection in patients following allogeneic stem cell transplantation. The therapy consists of donor-derived T lymphocytes (both CD4+ and CD8+ subsets) that are expanded ex vivo to specifically recognize the CMV pp65 antigen, a major immunodominant protein of the virus. Once infused into the recipient, these antigen-specific T cells provide cellular immunity to control viral replication and prevent CMV-related disease in immunocompromised individuals. The therapy was evaluated in a Phase 1 pilot study to assess its safety and feasibility in post-transplant patients with malignant disease who are at high risk for CMV complications.
- Other names
- Donor-derived CMV pp65-specific T cellsCMV-specific T-cell adoptive immunotherapy
02
Targets
pp65/HLA-A*02:01 (CMV pp65 peptide-HLA-A*02:01 complex)
Beyond the preview
Go deeper on CMV pp65 Specific T Cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMV pp65 Specific T Cells.